为正生物IPO辅导：80后女总经理王小珍持股22%，丈夫任董事长、哥哥任董事

Core Viewpoint - Weizheng Biotechnology Co., Ltd. is progressing with its public offering of shares and listing on the Beijing Stock Exchange, despite a decline in revenue and a net loss for 2024 [1] Financial Performance - The operating revenue for 2024 was 51.20 million, a year-on-year decrease of 18.98% [1][2] - The net loss attributable to shareholders was 32.40 million, with a year-on-year reduction in losses of 32.11% [1][2] - The gross profit margin improved to 35.48%, compared to 27.44% in the previous year [1][2] Shareholding Structure - As of the end of 2024, major shareholders include Wang Xiaozhen (22.28%), Wang Dezeng (13.5%), Xu Jindui (7.3%), and Liang Jianzhong (6.47%) [3] - The actual controller of the company is Lin Zhikang, who is also the general partner of Xiamen Youwei Kang Investment Partnership [2][3] Management Team - Lin Zhikang serves as the chairman, Wang Xiaozhen as the general manager, and Wang Dezeng as a board member [6][7][8][9] - The management team has a diverse background in biotechnology and management roles within the industry [7][8][9]